The Incidence, Mortality, and Survival of Malignant Non-Small Cell Lung Cancer (NSCLC) in the United States: A Surveillance Epidemiology and End Results (SEER) 2000-2022 Database Analysis
Author(s)
Dimitrije Grbic, PhD (c), Filip Stanicic, PhD (c), Vlad Zah, DPhil.
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
Presentation Documents
OBJECTIVES: Investigating epidemiology and survival of non-small cell lung cancer (NSCLC) in the US using the most recent Surveillance, Epidemiology, and End Results (SEER) database released in April 2025.
METHODS: SEER*Stat was used to retrieve and analyze data from 17 US cancer registries (2000-2022). The target population consisted of patients with malignant NSCLC. Outcomes were crude incidence and mortality rates and survival.
RESULTS: There were 685,611 NSCLS patients. Most patients were 65+ years old (67.5%), males (52.4%), non-Hispanic Whites (75.5%), married (50.9%), from metropolitan counties (84.6%), and with $65,000-$90,000 annual household income (AHI) (46.1%). The incidence of NSCLC was 36.1 per 100,000 population. The incidence rates (per 100,000 population) were higher among patients with 65+ years (188.7), males (38.2), non-Hispanic Whites (50.1), from non-metropolitan counties (53.9), and with <$40,000 AHI (67.9). Incidence rates significantly decreased between 2000 and 2022 with -1.1 annual percent change (p<0.050). The mortality of NSCLC was 30.2 per 100,000 population. The mortality rates (per 100,000 population) were higher among patients with 65+ years (171.9), males (33.2), non-Hispanic Whites (42.3), from non-metropolitan counties (46.0), and with <$40,000 AHI (60.2). The survival of NSCLC was 49.2% at 1-year and 19.7% at 5-year endpoints. Survival rates decreased with aging and were higher among females than males (23.9% vs. 16.2% at 5-year endpoint). Regarding race/ethnicity, the 5-year survival rates were the lowest for non-Hispanic Blacks (16.3%) and non-Hispanic American Indians/Alaska Natives (18.0%). Patients from non-metropolitan counties had lower survival rates than those from metropolitan counties (17.4% vs. 20.2% at 5-year endpoint). Lower AHI was associated with shorter survival.
CONCLUSIONS: These findings show a concerning burden of NSCLC in the US. Although the annual incidence is slightly decreasing, less than 1 in 5 patients on average would survive a 5-year period. New effective treatments and social equality in healthcare are needed.
METHODS: SEER*Stat was used to retrieve and analyze data from 17 US cancer registries (2000-2022). The target population consisted of patients with malignant NSCLC. Outcomes were crude incidence and mortality rates and survival.
RESULTS: There were 685,611 NSCLS patients. Most patients were 65+ years old (67.5%), males (52.4%), non-Hispanic Whites (75.5%), married (50.9%), from metropolitan counties (84.6%), and with $65,000-$90,000 annual household income (AHI) (46.1%). The incidence of NSCLC was 36.1 per 100,000 population. The incidence rates (per 100,000 population) were higher among patients with 65+ years (188.7), males (38.2), non-Hispanic Whites (50.1), from non-metropolitan counties (53.9), and with <$40,000 AHI (67.9). Incidence rates significantly decreased between 2000 and 2022 with -1.1 annual percent change (p<0.050). The mortality of NSCLC was 30.2 per 100,000 population. The mortality rates (per 100,000 population) were higher among patients with 65+ years (171.9), males (33.2), non-Hispanic Whites (42.3), from non-metropolitan counties (46.0), and with <$40,000 AHI (60.2). The survival of NSCLC was 49.2% at 1-year and 19.7% at 5-year endpoints. Survival rates decreased with aging and were higher among females than males (23.9% vs. 16.2% at 5-year endpoint). Regarding race/ethnicity, the 5-year survival rates were the lowest for non-Hispanic Blacks (16.3%) and non-Hispanic American Indians/Alaska Natives (18.0%). Patients from non-metropolitan counties had lower survival rates than those from metropolitan counties (17.4% vs. 20.2% at 5-year endpoint). Lower AHI was associated with shorter survival.
CONCLUSIONS: These findings show a concerning burden of NSCLC in the US. Although the annual incidence is slightly decreasing, less than 1 in 5 patients on average would survive a 5-year period. New effective treatments and social equality in healthcare are needed.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH247
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Oncology